Guilu Erxian Glue Inhibits Autophagy via Keap1/Nrf2 in Spermatogonial Cells

Study Background and Research Question

Male infertility affects approximately 8–12% of reproductive-age couples worldwide, with sperm defects accounting for about half of these cases (source: paper). Despite this prevalence, the molecular mechanisms underlying sperm dysfunction—particularly those linked to oxidative damage—remain incompletely defined. Oxidative stress is a well-established contributing factor in male infertility, leading to impaired cell viability and increased cellular damage. Traditional Chinese Medicine (TCM) formulations, including Guilu Erxian glue (GLEXG), have a historical role in addressing reproductive health, yet their precise cellular mechanisms require rigorous exploration. The present study investigates how GLEXG mitigates oxidative damage in mouse GC-1 spermatogonial cells (MGS) by modulating autophagy through the Keap1/Nrf2 pathway, potentially offering new molecular insights for therapeutic innovation (source: paper).

Key Innovation from the Reference Study

The central innovation of this research is the identification of GLEXG's role in inhibiting excessive autophagy and alleviating oxidative damage in spermatogonial cells via modulation of the Keap1/Nrf2 signaling axis. Prior studies have implicated Keap1/Nrf2 in antioxidant defense, but this work provides direct evidence that a TCM formula can downregulate autophagy-associated vesicle formation and oxidative injury in a mammalian germ cell model. The study further differentiates itself by using rapamycin-induced autophagy as a comparator, thereby situating its mechanistic findings within the broader context of established autophagy and mTOR pathway research (source: paper).

Methods and Experimental Design Insights

The research employed a robust in vitro model using mouse GC-1 spermatogonial cells subjected to hydrogen peroxide (H₂O₂) to induce oxidative stress. Key methodological features included:

• Cell viability assessment via cell counting kit-8 (CCK-8) assay.
• ROS and MDA quantification using flow cytometry and ELISA, respectively.
• Autophagy marker analysis (p62, LC3B, Keap1, Nrf2) through Western blotting, immunofluorescence, and quantitative RT-PCR.
• Transmission electron microscopy (TEM) to observe autophagic vesicle morphology.
• Gene silencing using Keap1-siRNA to validate pathway specificity.

Importantly, the study included experimental arms with rapamycin treatment—a well-characterized mTOR inhibitor known to activate autophagy—as well as GLEXG treatment in both wild-type and Keap1-silenced cells. This allowed the team to dissect the interplay between GLEXG, autophagy, and the Keap1/Nrf2 axis with high specificity (source: paper).

Protocol Parameters

• Cell viability assay | CCK-8, absorbance at 450 nm | GC-1 spermatogonial cells | Sensitive measurement of proliferation and cytotoxicity | paper
• Oxidative damage induction | H₂O₂ at defined concentration | MGS cell model | Reproducible oxidative stress induction | paper
• GLEXG-enriched serum treatment | 10% (v/v) | Cell culture, in vitro | Mimics physiological exposure to TCM components | paper
• Rapamycin treatment | concentration as per positive control, typically 0.1–20 nM | Activation of autophagy in MGS cells | Benchmark for mTOR pathway modulation | workflow_recommendation
• siRNA transfection | Keap1-siRNA-2311 | Gene knockdown validation | Targeted pathway specificity | paper
• Autophagy marker quantification | Western blot (p62, LC3B, Nrf2, Keap1), immunofluorescence | Molecular readouts | Pathway interrogation | paper

Core Findings and Why They Matter

Upon H₂O₂-induced oxidative challenge, MGS cells exhibited reduced viability and increased ROS and MDA—hallmarks of oxidative damage. GLEXG treatment (10% serum) led to significant improvements: cell viability increased (P = .0002), while ROS and MDA levels were reduced (P = .0105 and P = .0033, respectively) (source: paper). Mechanistically, GLEXG:

• Upregulated p-mTOR, Nrf2, and p62 protein levels while downregulating Keap1 and the LC3B-II/LC3B-I ratio in rapamycin-treated cells.
• Decreased the number of pathologically enlarged autolysosomes (TEM evidence), indicating suppression of excessive autophagy.
• Demonstrated similar effects in Keap1-silenced cells, confirming pathway specificity.

These results position GLEXG as a modulator of both oxidative stress and autophagy, specifically through the Keap1/Nrf2 axis, and suggest a potential integrative approach for ameliorating male infertility linked to oxidative damage.

Comparison with Existing Internal Articles

Rapamycin (Sirolimus) is widely recognized as a potent, specific mTOR inhibitor used to interrogate autophagy and cell proliferation pathways in a variety of research contexts (source: internal article). In the current study, rapamycin served as a positive control to induce autophagy, thereby allowing the effects of GLEXG to be measured in a setting of heightened autophagic flux. This mirrors best practices in cell signaling research, where validated mTOR inhibitors like Rapamycin (IC50 ~0.1 nM) are deployed to dissect pathway dependencies (source: product_spec). Furthermore, prior internal resources emphasize Rapamycin's application in cancer biology, immunology, and mitochondrial disease models—domains where modulation of the AKT/mTOR, ERK, and JAK2/STAT3 pathways underpin both cell proliferation suppression and apoptosis induction (internal article). While the reference study focuses on the Keap1/Nrf2 axis in germ cells, its experimental approach aligns with these established practices, reinforcing the translational relevance of pathway-specific autophagy modulation.

Limitations and Transferability

Despite its rigorous approach, the study is limited to an in vitro mouse spermatogonial cell line, which may not fully recapitulate the complexity of human male infertility. The concentration and bioavailability of GLEXG components in vivo remain to be established, and direct comparison with clinical samples or patient-derived cells would strengthen translational relevance. Additionally, while the interplay between the Keap1/Nrf2 and mTOR pathways is suggested, the precise molecular crosstalk warrants further elucidation. Workflow transferability to other cell types or oxidative disease models should be approached with careful optimization, guided by established controls such as Rapamycin.

Research Support Resources

For researchers aiming to model autophagy regulation or oxidative stress in cell systems, reproducible tools are essential. Rapamycin (Sirolimus) (SKU A8167) from APExBIO is a validated, highly potent inhibitor of mTOR signaling (IC50 ≈ 0.1 nM), widely used to induce or modulate autophagy for mechanistic studies in cell biology and disease modeling (source: product_spec). Utilizing such reference compounds in parallel with pathway-targeted interventions—such as herbal extracts or gene knockdown—can enhance the interpretability and translational potential of experimental findings.